DURECT (DRRX)
(Real Time Quote from BATS)
$1.37 USD
+0.01 (0.74%)
Updated Jul 17, 2024 09:58 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
DURECT Corporation [DRRX]
Reports for Purchase
Showing records 81 - 100 ( 143 total )
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
All About DUR-928:Two Shots on Goal in 2018; Upgrading to Buy, $3.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
3Q Recap: Focused on Multiple POC Trials of DUR-928 in 2018; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Posimir Fails to PERSIST; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
2Q Recap: Pivotal Posimir Data and Initiating a Phase 2 DUR-928 Study in PSC, Both in 4Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Early Completion of Enrollment for PERSIST Is an Incremental Positive for Posimir; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
1Q Recap: Novartis Partnership for Posimir; Clear Development Path for DUR-928; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
NASH SPLASH: Highlights From Our Inaugural NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Agenda for Our First Annual NASH Investor Conference on April 3 in NY
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
4Q16 Recap: First Clinical Data of DUR-928 in NASH Expected Next Month; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
We are assume coverage with a Buy rating and $3.00 price target.
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G